leisure time -WSS

leisure time

author：explore 2025-09-30 00:51:13 - browse：78221

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Why Charlie Gard's case is so disturbing to Americans

WSS

Chan Zuckerberg Biohub Chicago to focus on inflammation

Readout Newsletter: BridgeBio, Akero, and human embryo models

Chan Zuckerberg Biohub Chicago to focus on inflammation

Why age limits for politicians are a terrible idea

Streamlined flu vaccines recommended by FDA advisory panel

Bill would stop addiction treatment from triggering child abuse inquiry

hotspot

leisure time

explore

Cancer drug shortages should be causing more outrage

Liquid biopsy for lung cancer is launched by Delfi

Hepatitis C has a cure — but many Americans still lack access to it

Senate panel eyes new effort on drug shortages

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Walensky prepares to leave CDC — and Congress — behind

Stem cell biologist probes earliest stages of human development

State Dept. review finds Biden bears some blame for Afghanistan failures

$1 billion proposal to grow Boston, Massachusetts biotech

hotspot

The untold story of TV’s first prescription drug ad

Pregnant women don't need prenatal multivitamins, study concludes

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

For AI in health care standards, federal regulators join with industry group

Harvard's David Sinclair gets blowback over aging

The future of health care in the House

focus

explore

leisure time

explore